Bausch Health Has Full Plate While Trimming Debt, Setting Table For Bausch + Lomb Separation

With Decision Pending On Spinout Method, SEC Form For IPO Filed

Bausch Health says it’s continuing a recovery from the disaster previous management left, when the firm operated as Valeant Pharmaceuticals, even though it reported a $595m net loss for Q2. “We've been trying to solve this debt issue for the company,” says CEO Joseph Papa.

• Source: Alamy

Bausch Health Companies Inc. adds more to its reorganizing plate with each space that opens from moving a piece off while the main course still is under preparation – separation of its Bausch + Lomb Inc. division into a standalone business.

With its second-quarter results on 3 August, the Canadian firm offered an appetizer for its Bausch + Lomb plans. Although...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Deals

More from Business